Board summary
Key figures
41,974
Registered population
61.5% aged 18–64
13.8%
Aged 65+
ICB 19.9% · England 17.9%
27.3%
Ethnic minority (non-White)
10.4% Asian · England 9.6%
10.9%
In IMD quintile 1
ICB 17.1% · England 21.0%
~4,065
Core20 residents (est.)
Resident basis; registered basis ~4,760 · see page 3
7,170
Hypertension register
+20.19% in 3 yrs · England +5.60%
371
SMI register
33.5% of Dartford's
541
COPD register
Reviews -17.02% in 3 yrs
Forecast to 2030
11,394
Hypertension patients, 2030
+4,224 on today
89.8%
QRISK ≥20% on statins, 2030
+10.05pp over 3 yrs
3.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension BP control lags national benchmark.
Hypertension treated to target is 60.3% (England 70.3%, down 8.1%), and under-80s BP control is 56.5% (England 67.8%, down 9.4%).
Pre-school booster and MMR2 below 95% target.
Age-5 4-in-1 coverage is 79.7% (15.3 pp below the 95.0% target) and MMR2 is 81.2%, 10.8 pp below age-5 MMR1 at 92.0%.
Rapid growth in lipid-lowering therapy uptake.
QRISK ≥ 20% lipid-lowering therapy rose +18.8% (England +6.2%) to 63.7% (England 63.6%), while CKD lipid therapy reaches 77.3% (England 70.3%).
Population, age and ethnicity
Younger age structure and 27.3% ethnic minority residents may influence primary care demand
Across 41,974 registered patients, Dartford Central PCN has a younger demographic: 24.7% are aged 0-17 against 23.3% in Dartford, 20.7% in NHS Kent and Medway ICB and 19.6% in England, led by Temple Hill Surgery at 28.1%. Conversely, 13.8% are aged 65+ (Dartford 15.1%, ICB 19.9%, England 17.9%). Census resident estimates show 27.3% ethnic minority residents, including 11.4% Black or Black British (Dartford 10.5%, ICB 3.1%, England 4.2%) and 10.4% Asian or Asian British (Dartford 9.9%, ICB 4.7%, England 9.6%). Projected list growth is 6.0% to 2030 (methodology unverified).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Dartford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Dartford LA) | 2,006 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Dartford LA) | 1,000 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Dartford LA) | 14.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is moderate at PCN level and sharply uneven between practices
Dartford Central PCN's Core20 share is 10.9%, above Dartford (9.8%) but below NHS Kent and Medway ICB (17.1%) and England (21.0%). The weighted practice share is 11.3%, showing a 0.41 pp difference. Practice share spans 13.5 pp: Horsman's Place Surgery has the highest concentration (19.5%; 1,852 estimated patients), whereas Temple Hill Surgery holds the largest volume (2,382 estimated patients at 10.1%). Resident Core20 estimates total about 4,100. Services could balance intensive targeted outreach at high-concentration sites against routine management at high-volume practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
371
SMI register
0.91% recorded prevalence
294
Learning disability register
0.72% recorded prevalence
14
Care homes, 635 beds
In the PCN catchment
8.6%
Provide unpaid care
Dartford, Census 2021
Recorded learning disability prevalence is 0.7% (294 patients; Dartford 0.6%, NHS Kent and Medway ICB 0.6%, England 0.6%), representing 38.4% of the borough register, alongside 371 patients on the severe mental illness register (0.9%; Dartford 0.8%, England 1.0%). Catchment care homes total 14 sites with 635 beds. The PCN accounts for 38.4% of Dartford borough's learning disability register, indicating a concentrated caseload for routine clinical review across member practices.
Severe mental illness: physical health checks
SMI recorded prevalence is 0.9% (England 1.0%). Physical health checks trail England across individual elements: 80.7% received a blood pressure check (England 83.4%) and 78.5% had BMI recorded (England 82.1%), leaving physical risk monitoring incomplete for this cohort.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,170
Hypertension register
+20.19%
Register growth, 3 yrs
Dartford +7.12% · England +5.60%
−5.85pp
BP control, under 80
≤140/90 · −1.50pp aged 80+
+4,224
More patients by 2030
Forecast 11,394 (25.35%)
Hypertension case-finding and control
Hypertension prevalence reached 17.6% (7,170 patients), rising +20.2% over three years (Dartford +7.1%, England +5.6%). However, monitoring and control trail benchmarks: recent blood pressure checks reached 82.3% (England 90.0%), and patients treated to target fell 8.1% to 60.3% (England 70.3%). Among patients aged under 80, control to <= 140/90 mmHg fell 9.4% to 56.5% (England 67.8%), with practice rates at 43.9% at Horsman's Place Surgery and 59.3% at Temple Hill Surgery. This could reflect routine review capacity lagging rapid case-finding; a recall audit would test it. Blood pressure control trails England and ICB comparators, meaning review capacity should be prioritised for systematic recall of uncontrolled patients.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 63.7%, rising +18.8% over three years (England +6.2% to 63.6%). Additionally, CKD lipid-lowering therapy reached 77.3% (England 70.3%, Dartford 74.3%). Lipid management is above or in line with national benchmarks, showing an opportunity to sustain proactive treatment across high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 60,911 | £1.90 | £1.90 | £1.86 | £115,731 |
| Cardiovascular (all), 2025 | 73,226 | £3.84 | £3.57 | £3.33 | £281,188 |
For lipid-modifying drugs in 2026, the PCN prescribed 60,911 items totalling £115,731 at £1.90 per item. This was £2,436 more than at England's unit cost of £1.86, and equal to NHS Kent and Medway ICB's £1.90. Unit costs sit slightly above England while matching the ICB, indicating that the PCN could prioritise volume reviews over unit-cost switching.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.36%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−5.50%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.3% (England 1.9%, Dartford 1.6%), having fallen 11.1% over three years (England +2.6%), while 12-month COPD reviews fell 17.0% (England +2.8%) to 68.8% (England 76.4%). Asthma prevalence is 4.8% (England 6.6%); reviews stand at 67.4% (England 65.7%), with an estimated 589 patients on the 1,809 register lacking a 12-month review. Youth asthma prescribing is 893 items per 1,000 (England 1,488). This could reflect review capacity trailing case-finding; a recall audit would test it.
Cancer register and children's immunisation
Cancer prevalence is 3.3% (1,338 patients), below England (3.8%). All childhood immunisation cohorts sit below the 95.0% target: at 12 months, 6-in-1 coverage is 85.7% (England 91.0%). At age five, 4-in-1 booster coverage is 79.7% (15.3 pp below target; England 80.9%) and MMR dose 2 is 81.2% (England 82.8%), trailing first-dose coverage of 92.0% by 10.8 pp. This leaves significant pre-school immunisation gaps requiring systematic recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of staged cancers (4,661 of 8,384) were diagnosed at stage 1 or 2, in line with England (55.3%) and at a distance of -19.4 pp to the 75.0% national ambition. Across all registered cancers, 63.6% had a known stage (England 67.0%). Sizing indicates the ICB requires 1,627 extra early-stage diagnoses annually to reach 75.0%, having changed +2.2 pp since 2013. Locally, cervical screening in women aged 25-49 is 63.9% (England 66.8%), changing -2.9% over three years (England -1.0%). Systematic screening recall could help identify early pre-cancerous lesions before symptomatic progression.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Dartford and Gravesham NHS Trust met the 28-day faster diagnosis standard at 78.1% (standard 75.0%; Lewisham and Greenwich NHS Trust 83.7%, England 79.3%, NHS Kent and Medway Integrated Care Board 76.8%) and the 31-day standard at 97.5% (standard 96.0%; England 92.5%). However, the Trust's 62-day referral to treatment was 63.6%, showing a distance of -21.4 pp to the 85.0% standard (Lewisham and Greenwich NHS Trust 69.0%, England 71.2%, ICB 75.9%). For all diagnostic tests, 8.4% waited 6+ weeks at the Trust (England 23.1%). Delays beyond diagnosis could reflect specialist treatment capacity rather than diagnostic backlogs.
| Pathways within standard (%) | Dartford and Gravesham | Lewisham and Greenwich | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 83.74 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 95.24 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 68.98 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | Lewisham and Greenwich | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 2.30 | 21.40 |
| CT | 2.08 | — | 10.21 | 9.92 |
| Echocardiography | 3.90 | — | 6.82 | 28.48 |
| Colonoscopy | 0.40 | — | 19.65 | 30.83 |
| Gastroscopy | 0.00 | — | 9.42 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 27.58 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). At local authority and system level (not PCN performance), provisional experimental community services data for June 2026 recorded 210,170 care contacts and 265,905 care activities across 60,605 Kent residents, within an ICB total of 254,055 contacts and 297,595 activities. Adults aged 65+ accounted for 65.8% of Kent contacts (138,250), reflecting a high concentration of community contacts among older residents across the wider system.
Practice variation and patient experience
Patient experience varies by 23.8 percentage points across practices alongside uneven phone access
In 2025/26, QOF overall achievement was 90.4% at Redwood Practice, 89.3% at Temple Hill Surgery, and 82.8% at Horsman's Place Surgery (England 92.5%). Clinical achievement was 100.0% at Redwood Practice, 98.6% at Temple Hill Surgery, and 89.2% at Horsman's Place Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Horsman's Place | 94 | 19.5 | 46.8% | 69.0% | 77.3% |
| Redwood Practice | 117 | 6.0 | 30.0% | 66.0% | 72.9% |
| Temple Hill | 88 | 10.1 | 29.9% | 72.1% | 53.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 tracked three-year trends, 17 trail England, led by contracting disease registers
Across 25 tracked three-year trends, 17 trail England. Dementia prevalence fell 18.7% (England +6.0%), COPD reviews fell 17.0% (England +2.8%), and heart failure reviews fell 14.3% (England +8.7%) to 73.5% (England 78.5%). Learning disability prevalence fell 7.9% (England +5.4%). Conversely, three-year relative growth outpaced England in breast screening (+29.9% vs England +8.4%), QRISK ≥ 20% lipid therapy (+18.8% vs England +6.2%), and diabetes HbA1c control without frailty (+12.9% vs England +4.4% to 56.1%). This could reflect review capacity trailing case-finding; a recall audit would test it.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
COPD reviews
COPD register
Learning disability register
Breast screening (53-70)
QRISK statin treatment
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Dartford | Asset | PCN | Dartford |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (635 beds) | n/a | Schools (catchment) | 79 | n/a |
| Children's centres | 5 | 7 | Places of worship | 36 | 41 |
| Libraries | 5 | 7 | Homelessness support (VCS) | n/a | 1 |
| Day centres (VCS) | 7 | 5 | Children and young people (VCS) | 1 | 1 |
| Carers support groups (VCS) | n/a | 3 | Primary schools (LA maintained) | 5 | 6 |
| Primary academies | 14 | 22 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension BP review and titration recall
On the 7,170 register, BP treated to target is 60.3% (England 70.3%, fell 8.1%), and under-80s control is 56.5% (England 67.8%, fell 9.4%; Horsman's Place Surgery 43.9%, Temple Hill Surgery 59.3%). For discussion, run pharmacist-led recall and titration clinics for hypertensive patients above target, starting with under-80s. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Respiratory and heart failure review recall
Asthma reviews are 67.4% (589 of 1,809 unreviewed). COPD reviews fell 17.0% to 68.8% (England 76.4%; gap +136 to +254) and heart failure fell 14.3% to 73.5% (England 78.5%; gap +47 to +170). For discussion, use a combined recall template to review unreviewed asthma, COPD and heart failure patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Pre-school booster and cervical screening recall
Age-5 4-in-1 coverage is 79.7% (below the 95.0% target by 15.3 pp) and MMR2 is 81.2% (10.8 pp below MMR1 at 92.0%; 13.3 pp at Temple Hill Surgery). Cervical screening fell 2.9% to 63.9% (England 66.8%). For discussion, audit overdue pre-school immunisation and cervical screening lists with flexible clinics. Low cost, quick to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric access and clinic review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension BP review and titration recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Respiratory and heart failure review recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
| Option 3 · Pre-school booster and cervical screening recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
